Computationally designed pyocyanin demethylase acts synergistically with tobramycin to kill recalcitrant Pseudomonas aeruginosa biofilms
Abstract
Pseudomonas aeruginosa is an opportunistic human pathogen that develops difficult-to-treat biofilms in immunocompromised individuals, cystic fibrosis patients, and in chronic wounds. P. aeruginosa has an arsenal of physiological attributes that enable it to evade standard antibiotic treatments, particularly in the context of biofilms where it grows slowly and becomes tolerant to many drugs. One of its survival strategies involves the production of the redox-active phenazine, pyocyanin, which promotes biofilm development. We previously identified an enzyme, PodA, that demethylated pyocyanin and disrupted P. aeruginosa biofilm development in vitro. Here, we asked if this protein could be used as a potential therapeutic for P. aeruginosa infections together with tobramycin, an antibiotic typically used in the clinic. A major roadblock to answering this question was the poor yield and stability of wild-type PodA purified from standard Escherichia coli overexpression systems. We hypothesized that the insufficient yields were due to poor packing within PodA's obligatory homotrimeric interfaces. We therefore applied the protein design algorithm, AffiLib, to optimize the symmetric core of this interface, resulting in a design that incorporated five mutations leading to a 20-fold increase in protein yield from heterologous expression and purification and a substantial increase in stability to environmental conditions. The addition of the designed PodA with tobramycin led to increased killing of P. aeruginosa cultures under oxic and hypoxic conditions in both the planktonic and biofilm states. This study highlights the potential for targeting extracellular metabolites to assist the control of P. aeruginosa biofilms that tolerate conventional antibiotic treatment.
Additional Information
© 2021 National Academy of Sciences. Published under the PNAS license. Edited by David Baker, University of Washington, Seattle, WA, and approved February 16, 2021 (received for review October 29, 2020). This work was supported by the Schwartz/Reisman Collaborative Science Program; NIH Grants 1R01AI127850-01A1 and 1R01HL152190-01; and the Doren Family Foundation. Research in the S.J.F. laboratory was further supported by the Dr. Barry Sherman Institute for Medicinal Chemistry; a Consolidator Grant from the European Research Council (815379); and the Israel Science Foundation (1844). R.L.-S. was supported by a fellowship from the Arianne de Rothschild Women Doctoral Program. We thank Steven Wilbert and Melanie Spero for assistance with ABBA experiments; Steven Wilbert for image analysis; John Ciemniecki for image and statistical analyses; Louise Siskel for experimental assistance; and Scott Saunders for providing growth curve fitting software. Data Availability: All study data are included in the article and/or supporting information. Author contributions: C.M.V., R.L.-S., O.K., S.J.F., and D.K.N. designed research; C.M.V., R.L.-S., and O.K. performed research; C.M.V., R.L.-S., O.K., S.J.F., and D.K.N. analyzed data; and C.M.V., R.L.-S., O.K., S.J.F., and D.K.N. wrote the paper. Competing interest statement: C.M.V., R.L.-S., O.K., S.J.F., and D.K.N. are named inventors on patents filed by Caltech and the Weizmann Institute on the design methods. This article is a PNAS Direct Submission. This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2022012118/-/DCSupplemental.Attached Files
Published - e2022012118.full.pdf
Supplemental Material - pnas.2022012118.sapp.pdf
Supplemental Material - pnas.2022012118.sd01.txt
Supplemental Material - pnas.2022012118.sd02.txt
Supplemental Material - pnas.2022012118.sd03.txt
Supplemental Material - pnas.2022012118.sd04.txt
Supplemental Material - pnas.2022012118.sd05.txt
Files
Name | Size | Download all |
---|---|---|
md5:dfc1aa6b16a8ed9a344f9ec8c5271205
|
6.9 MB | Preview Download |
md5:0cae2bf2f4709471ba04c671cd76fcb1
|
4.4 kB | Preview Download |
md5:9514b9128a021dbacc9bf814f831eabe
|
221 Bytes | Preview Download |
md5:cba0e827014f9ccd253bfe2ba52e43f6
|
2.6 kB | Preview Download |
md5:c3e21f2974f30963e96259093bad5559
|
22.4 kB | Preview Download |
md5:7cf9bbcad649341bc079f99c02beb3a3
|
1.2 MB | Preview Download |
md5:c231435e1dbd9f90ad3f0d6bdea8674a
|
3.7 kB | Preview Download |
Additional details
- PMCID
- PMC8000102
- Eprint ID
- 108445
- Resolver ID
- CaltechAUTHORS:20210316-072135929
- Schwartz/Reisman Collaborative Science Program
- 1R01AI127850-01A1
- NIH
- 1R01HL152190-01
- NIH
- Doren Family Foundation
- Dr. Barry Sherman Institute for Medicinal Chemistry
- 815379
- European Research Council (ERC)
- 1844
- Israel Science Foundation
- Arianne de Rothschild Women Doctoral Program
- Created
-
2021-03-19Created from EPrint's datestamp field
- Updated
-
2023-07-17Created from EPrint's last_modified field
- Caltech groups
- Division of Geological and Planetary Sciences, Division of Biology and Biological Engineering